Bryant Furlow, Author at Cancer Therapy Advisor - Page 70 of 70
Bryant Furlow

Bryant Furlow

Contributing Writer
Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a bachelor of science in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research, and health care policy. Prior to becoming a contributor to Haymarket Media in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.

All articles by Bryant Furlow

No Survival Gains Seen with Nimotuzumab in Glioblastoma but More Study Warranted in Patients with MGMT Nonmethylated Glioblastoma

Nimotuzumab does not improve survival among newly diagnosed glioblastoma patients when added to standard temozolomide chemoradiotherapy, but warrants further study among patients with MGMT nonmethylated glioblastoma, according to a randomized multicenter phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.

Next post in Skin Cancer